Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.

Drug Metab Pharmacokinet

Laboratory for Innovative Therapy Research, Shionogi & Co., Ltd., Osaka, Japan. Electronic address:

Published: February 2022

The brain penetration of 19 drugs, including P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) substrates, was compared among mice, cynomolgus monkeys and beagle dogs. The brain-to-plasma concentration ratios (K) of the tested compounds in monkey and dog showed good correlation, whereas species differences were observed between non-rodents (monkey/dog) and rodents (mouse). In particular, the K values of 7 compounds out of 12 P-gp substrates (K ratio in P-gp knockout mice versus wild-type mice ≥3) in monkey and dog were more than three-fold higher than those in mice and a similar trend was observed in the brain-to-plasma unbound concentration ratios (K). The cerebral spinal fluid (CSF) drug concentrations (C), a surrogate for unbound brain concentration (C), were also compared between dog and monkey, and the CSF-to-plasma unbound concentration ratios (K) of BCRP substrates in dog were notably higher than those in monkey, although non-bcrp substrates showed good correlation. Also, the K values of BCRP substrates in dog were clearly higher than the K values, indicating that the dog C of BCRP substrates was not suitable as a surrogate of C. These observations should be useful when selecting the appropriate animal models for CNS drug discovery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dmpk.2021.100426DOI Listing

Publication Analysis

Top Keywords

bcrp substrates
20
monkey dog
12
concentration ratios
12
brain penetration
8
good correlation
8
unbound concentration
8
substrates dog
8
substrates
7
dog
7
bcrp
5

Similar Publications

Background And Objective: This study provides a physiologically based pharmacokinetic (PBPK) model-based analysis of the potential drug-drug interaction (DDI) between cyclosporin A (CsA), a breast cancer resistance protein transporter (BCRP) inhibitor, and methotrexate (MTX), a putative BCRP substrate.

Methods: PBPK models for CsA and MTX were built using open-source tools and published data for both model building and for model verification and validation. The MTX and CsA PBPK models were evaluated for their application in simulating BCRP-related DDIs.

View Article and Find Full Text PDF

Endogenous plasma riboflavin is not a viable BCRP biomarker in human.

Clin Transl Sci

December 2024

Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.

Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co-administration of 375 mg once daily (q.

View Article and Find Full Text PDF

Effect of furmonertinib on the pharmacokinetics of rivaroxaban or apixaban in vivo.

J Chromatogr B Analyt Technol Biomed Life Sci

December 2024

Department of Pharmacy, Hebei General Hospital, Shijiazhuang, China; Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, China. Electronic address:

Article Synopsis
  • Furmonertinib is a third generation EGFR-TKI used to treat non-small cell lung cancer (NSCLC), which often coexists with venous thromboembolism (VTE) that is treated using direct oral anticoagulants (DOACs) like rivaroxaban and apixaban.
  • This study investigated how furmonertinib affects the pharmacokinetics of these DOACs in rats, revealing that it significantly increases the concentration and overall exposure (C and AUC) of both rivaroxaban and apixaban while decreasing their clearance (CL/F) and volume of distribution (V/F).
  • The findings highlight the importance of recognizing furmonertinib’s impact on
View Article and Find Full Text PDF

One of the major risks associated with the concomitant use of herbal products and therapeutic drugs is herb-drug interactions (HDIs). The most common mechanism leading to HDIs is the inhibition and/or induction of transport proteins and drug-metabolizing enzymes by herbal ingredients, causing changes in the pharmacokinetic disposition of the victim drug. The present study aimed to determine the potential interactions of (UT) (cat's claw), a popular herb due to its supposed health benefits.

View Article and Find Full Text PDF

Interaction of Phyllanthus amarus extract and its lignans with human xenobiotic receptors, drug metabolizing enzymes and drug transporters.

J Ethnopharmacol

January 2025

National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, MS, 38677, United States; Department of Bio-Molecular Sciences, School of Pharmacy, The University of Mississippi, MS, 38677, United States. Electronic address:

Ethnopharmacological Relevance: Phyllanthus amarus is ethnomedicinally used to treat gallbladder stones, kidney stones and chronic liver diseases. P. amarus is gaining popularity as an ingredient in many botanical dietary supplements.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!